Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 5/20 | 0.72 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.72 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | GRM8 | O00222 | 2/20 | 0.72 |
| ▸ | GRM6 | O15303 | 2/20 | 0.72 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.72 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.72 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.72 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.72 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.72 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.72 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.72 |
| ▸ | GSR | P00390 | 1/20 | 0.72 |
| ▸ | GRM5 | P41594 | 1/20 | 0.72 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.72 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.72 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.72 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.72 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutamic Acid SCHEMBL5614072 | 1.00 | SLC1A3 (0.72) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| D-Glutamate SCHEMBL9176409 | 1.00 | SLC1A3 (0.72) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| Glutamic Acid SCHEMBL6130437 | 1.00 | SLC1A3 (0.72) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| Glutamic Acid SCHEMBL1126187 | 1.00 | SLC1A3 (0.72) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| D-Glutamate SCHEMBL3512077 | 1.00 | SLC1A3 (0.72) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| D-Glutamate SCHEMBL19876607 | 0.96 | SLC1A3 (0.67) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| Glutamic Acid SCHEMBL17926909 | 0.96 | SLC1A3 (0.67) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| Glutamic Acid SCHEMBL1365479 | 0.96 | SLC1A3 (0.67) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| Glutamic Acid SCHEMBL429944 | 0.94 | SLC1A3 (0.64) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| D-Glutamate SCHEMBL21410037 | 0.94 | SLC1A3 (0.64) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215527-B1 | HUMANIZED ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF | ANNEXON INC (US) | 2025-01-08 | — | — | EP | claimed |
| CN-110691609-B | Methods and compositions for inducing an immune response against clostridium difficile | 诺瓦瓦克斯股份有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-116987144-A | Lycium barbarum protein peptide with alpha-glucosidase inhibitory activity and preparation method thereof | 北方民族大学 | 2023-11-03 | — | — | CN | claimed |
| US-20200079880-A1 | METHODS FOR USE OF PROINSULIN TRANSFERRIN FUSION PROTEINS AS PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-03-12 | — | — | US | claimed |
| CN-110691609-A | Methods and compositions for inducing an immune response against clostridium difficile | 诺瓦瓦克斯股份有限公司 | 2020-01-14 | — | — | CN | claimed |
| US-10513563-B2 | Method for uses of proinsulin transferrin fusion proteins as prodrugs | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2019-12-24 | — | — | US | claimed |
| EP-3544992-A1 | G-PROTEIN-COUPLED RECEPTOR INTERNAL SENSORS | The Regents of The University of California (US) | 2019-10-02 | — | — | EP | claimed |
| WO-2018098262-A1 | G-PROTEIN-COUPLED RECEPTOR INTERNAL SENSORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-31 | — | — | WO | claimed |
| WO-2013177063-A1 | USES OF PROTEIN PRECURSORS AS PRODRUGS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2013-11-28 | — | — | WO | claimed |
| US-20130130967-A1 | Method for Uses of Protein Precursors as Prodrugs | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2013-05-23 | — | — | US | claimed |
| EP-1084137-A1 | PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2001-03-21 | — | — | EP | claimed |
| EP-0514509-B1 | COMPOSITION AND ITS PREPARATION PROCESS USING ANTIGEN CONJUGATED TO ENZYMATIC ACTIVITY FOR IMMUNOLOGICAL DIAGNOSIS AND CHAGAS' DISEASE IMMUNOLOGICAL DIAGNOSIS KITS, FOR INDIVIDUAL AND EPIDEMIOLOGICAL APPLICATION, BASED ON THAT COMPOSITION | FUNDACAO OSWALDO CRUZ (BR) | 2000-09-20 | — | — | EP | claimed |
| WO-1999064442-A1 | PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI S.P.A. (IT) | 1999-12-16 | — | — | WO | claimed |
| US-5977307-A | A LIGAND REACTIVE WITH A BRAIN CAPILLARY ENDOTHELIAL CELL RECEPTOR WHICH HAS FORMED A FUSION PROTEIN WITH A NEUROPHARMACEUTICAL AGENT. | ALKERMES, INC. | 1999-11-02 | — | — | US | claimed |
| US-5672683-A | NERVE GROWTH FACTOR OR CILIARY NEUROTROPHIC FACTOR BOUND AT ITS AMINO END TO THE CARBOXYL END OF A TRANSFERRIN, FOR DELIVERY ACROSS BLOOD BRAIN BARRIER | ALKERMES, INC. (US) | 1997-09-30 | — | — | US | claimed |
| EP-0708661-A1 | TRANSFERRIN RECEPTOR SPECIFIC LIGAND-NEUROPHARMACEUTICAL AGENT FUSION PROTEINS | ALKERMES, INC. (US) | 1996-05-01 | — | — | EP | claimed |
| WO-1995002421-A1 | TRANSFERRIN RECEPTOR SPECIFIC LIGAND-NEUROPHARMACEUTICAL AGENT FUSION PROTEINS | ALKERMES, INC. (US) | 1995-01-26 | — | — | WO | claimed |
| EP-0076557-B1 | PEPTIDES AND PSEUDOPEPTIDES IN WHICH THE N TERMINUS BEARS TWO SUBSTITUENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-11-13 | — | — | EP | claimed |
| US-4421744-A | OPIATE RECEPTOR ANTAGONISTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-12-20 | — | — | US | claimed |
| EP-0076557-A2 | Peptides and pseudopeptides in which the N terminus bears two substituents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-04-13 | — | — | EP | claimed |